Innovent Biologics, Inc./Eli Lilly and Company’s PD-1 inhibitor sintilimab fell hard at its US Food and Drug Administration advisory committee review for a host of reasons, not the least of which were the design, conduct and location of its Phase III trial.
But perhaps the biggest reason for sintilimab’s downfall was change – change in the lung cancer therapeutic landscape, change in...





